Atopic dermatitis: Phototherapy and systemic therapy

Dawn Marie Davis*, Jenna Borok, Jeremy Udkoff, Peter Lio, Jonathan Spergel

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.

Original languageEnglish (US)
Pages (from-to)118-123
Number of pages6
JournalSeminars in Cutaneous Medicine and Surgery
Volume36
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Phototherapy
Atopic Dermatitis
Immunosuppressive Agents
Mycophenolic Acid
Patient Preference
Azathioprine
Biological Factors
Methotrexate
Allergens
Cyclosporine
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Davis, Dawn Marie ; Borok, Jenna ; Udkoff, Jeremy ; Lio, Peter ; Spergel, Jonathan. / Atopic dermatitis : Phototherapy and systemic therapy. In: Seminars in Cutaneous Medicine and Surgery. 2017 ; Vol. 36, No. 3. pp. 118-123.
@article{b5357344b48142a3aaee5426ef4d8f27,
title = "Atopic dermatitis: Phototherapy and systemic therapy",
abstract = "The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.",
author = "Davis, {Dawn Marie} and Jenna Borok and Jeremy Udkoff and Peter Lio and Jonathan Spergel",
year = "2017",
month = "9",
day = "1",
doi = "10.12788/j.sder.2017.027",
language = "English (US)",
volume = "36",
pages = "118--123",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Atopic dermatitis : Phototherapy and systemic therapy. / Davis, Dawn Marie; Borok, Jenna; Udkoff, Jeremy; Lio, Peter; Spergel, Jonathan.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 36, No. 3, 01.09.2017, p. 118-123.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Atopic dermatitis

T2 - Phototherapy and systemic therapy

AU - Davis, Dawn Marie

AU - Borok, Jenna

AU - Udkoff, Jeremy

AU - Lio, Peter

AU - Spergel, Jonathan

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.

AB - The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.

UR - http://www.scopus.com/inward/record.url?scp=85046084221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046084221&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2017.027

DO - 10.12788/j.sder.2017.027

M3 - Article

AN - SCOPUS:85046084221

VL - 36

SP - 118

EP - 123

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

IS - 3

ER -